Abstract-The benefits of the simultaneous administration of low doses of a calcium antagonist and a converting enzyme inhibitor in the treatment of hypertension and renal vasoconstriction are well established. The objective of this study was to evaluate whether the administration of low doses of a calcium antagonist and a converting-enzyme inhibitor have beneficial effects in treating the renal alterations induced by the acute administration of a cyclooxygenase inhibitor when nitric oxide synthesis is reduced. These effects were examined in anesthetized dogs before and during an acute sodium load. It was found that the intrarenal infusion of meclofenamate (5 g ⅐ kg
Abstract-The benefits of the simultaneous administration of low doses of a calcium antagonist and a converting enzyme inhibitor in the treatment of hypertension and renal vasoconstriction are well established. The objective of this study was to evaluate whether the administration of low doses of a calcium antagonist and a converting-enzyme inhibitor have beneficial effects in treating the renal alterations induced by the acute administration of a cyclooxygenase inhibitor when nitric oxide synthesis is reduced. These effects were examined in anesthetized dogs before and during an acute sodium load. It was found that the intrarenal infusion of meclofenamate (5 g ⅐ kg Ϫ1 ⅐ min
Ϫ1
), simultaneously with a low dose of N G -nitro-L-arginine methyl ester (1 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ), produced a 40% decrease of renal blood flow and glomerular filtration rate and a reduction in the renal excretory response to the sodium load. In a second group of dogs, intrarenal verapamil (0.5 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ) was effective in blocking the effects of nitric oxide and prostaglandin synthesis inhibition on sodium excretion and glomerular filtration rate but did not modify the effects on renal blood flow. An intrarenal infusion of trandolapril (0.3 g ⅐ kg Ϫ1 ⅐ min
) was effective in a third group of dogs in reducing the renal hemodynamic effects but not in preventing the antinatriuretic effect observed in the first group. Finally, in a fourth group, the simultaneous administration of verapamil and trandolapril was effective in treating all the renal changes induced by the cyclooxygenase inhibitor when nitric oxide synthesis was reduced. These results suggest that the combination of low doses of trandolapril and verapamil has additive effects in treating the renal vasoconstriction and antinatriuresis induced by the acute administration of a cyclooxygenase inhibitor, when nitric oxide synthesis is reduced. (Hypertension. 1998;31:657-664.) Key Words: vasoconstriction Ⅲ nitric oxide Ⅲ prostaglandin Ⅲ sodium sensitivity Ⅲ calcium antagonists converting enzyme inhibitors T he role of NO in mediating the renal response to short-and long-term increments in sodium intake is supported by studies showing that a decrease in NO synthesis reduces the renal ability to eliminate a sodium load and induces the development of sodium-sensitive hypertension. [1] [2] [3] [4] [5] On the other hand, it has been suggested that there is an important interaction between NO and PG in the regulation of the renal hemodynamic and excretory function. 2, 3 The existence of this interaction is supported by the results obtained in acute studies showing that meclofenamate administration produces renal vasoconstriction and reduces the excretory response to an acute sodium load when NO synthesis is reduced. 2, 3 These results support the hypothesis that the intake of cyclooxygenase inhibitors can induce the development of hypertension and important changes in renal function in situations where NO synthesis is partially decreased. In support of this hypothesis, it has been reported that NO synthesis seems to be reduced in salt-sensitive hypertension 6 and that the administration of a cyclooxygenase inhibitor induces an increase of arterial pressure in salt-sensitive hypertensive patients. 7 Recent studies of our group have demonstrated that captopril (0.8 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ) is only effective in treating the renal vasoconstriction, 3 and verapamil (2 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ) is effective in treating the antinatriuretic effects 8 induced by acute meclofenamate administration, when NO is reduced. Based on these findings and on the well-known pharmacological actions of calcium antagonists and CEIs, 9 -11 it could be expected that the combination of the two drugs would be effective in treating both renal effects produced by the acute inhibition of PG synthesis when NO production is reduced. Several studies have suggested that CEIs and calcium antagonists have additive and synergistic effects on sodium balance, on the renin-angiotensin system, 9 and in hypertension. 10, 11 The objective of the present study was to determine the effects of low doses of a CEI (trandolapril, 0.3 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ) and/or a calcium antagonist (verapamil, 0.5 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ) in blocking the renal vasoconstriction and antinatriuretic effects induced by the acute administration of a cyclooxygenase inhibitor when NO synthesis is partially reduced. These effects were evaluated in anesthetized dogs before and during an acute sodium load to examine whether simultaneous treatment with low doses of both drugs also improves the renal ability to eliminate an acute sodium load.
The results obtained may have some important clinical implications because of the following during aging: 1) there is an endothelial dysfunction, 6 2) the intake of anti-inflammatory drugs is enhanced, 1 and 3) the sodium sensitivity of blood pressure is increased. 13 That acute sodium load can be used for the assessment of salt responsiveness of blood pressure has been demonstrated by Weinberger et al. 14 The possible efficacy of combining low doses of these drugs in treating the renal effects induced by the acute administration of a cyclooxygenase inhibitor, when NO synthesis is reduced, may also have therapeutic importance since the incidence of side effects is dose-dependent.
10,15

Methods
Surgical Preparation
Experiments were accomplished in mongrel dogs of either sex (15 to 24 kg) anesthetized with sodium pentobarbital and were designed according to Guiding Principles in the Care and Use of Laboratory Animals approved by the Council of the American Physiological Society. Catheters were placed in the femoral artery for measurement of MAP and in the femoral vein for infusion of inulin and additional anesthetic (0.6 mL/min). Inulin was dissolved in isotonic saline and infused to achieve plasma fructose levels of 1.7 mmol/L. Both kidneys were exposed through flank incisions and the ureters cannulated to allow for comparison of the renal function of both kidneys. The dogs were placed in a metal frame that mimicked their usual standing position. The renal arteries were fitted with noncannulating electromagnetic flow probes and connected to flowmeters. Distal to the flow probe, a curved 23-gauge needle attached to polyethylene tubing was inserted into the renal arteries and connected to a peristaltic pump for infusion of saline or drugs (0.6 mL/min). Finally, a 45-minute stabilization period was allowed before experimental maneuvers were begun.
Experimental Groups
Group 1 (n‫)6؍‬
After two 15-minute control clearances, L-NAME (1 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ) was infused into the right renal artery until the end of the experiment. Fifteen minutes after the initiation of L-NAME infusion, meclofenamate (5 mg ⅐ kg Ϫ1 ⅐ min Ϫ1 ) was administered into both renal arteries for the duration of the experiment. Thirty minutes after initiating the meclofenamate infusion, two additional 15-minute clearances were obtained, and a 5% ECVE with isotonic saline was performed during 45 minutes. Two clearances were obtained: during the last 10 minutes of saline infusion and 10 minutes after cessation of this infusion. Finally, 30 minutes after the end of saline infusion, two additional 15-minute clearances were obtained.
Group 2 (n‫)6؍‬
After two 15-minute control clearances, L-NAME and meclofenamate were infused into the renal arteries in the same order and time sequence as in group 1. Thirty minutes after meclofenamate administration was initiated, two 15-minute clearances were obtained, and an infusion of verapamil (0.5 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ) into both renal arteries was begun. Two additional 10-minute clearances were then collected 30 minutes after the continuous infusion of verapamil started. Thereafter, the 5% ECVE was carried out during 45 minutes, and the clearances obtained, during and after the ECVE, were similar to those mentioned in group 1.
Group 3 (n‫)6؍‬
The experimental protocol accomplished in this group is similar to that of group 2, except that trandolapril (0.3 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ) was administered instead of verapamil. In preliminary experiments it was found that the dose of trandolapril used is effective in blocking the decrease in RBF and the increase in MAP induced by the intrarenal infusion of Ang I during 30 minutes (2 ng ⅐ kg
).
Group 4 (n‫)6؍‬
Group 4 received the same treatment as group 2, but both trandolapril
) were infused into the renal arteries instead of verapamil alone. Two 10-minute clearances were collected 30 minutes after the continuous infusion of verapamil and trandolapril started. Afterward, the 5% ECVE was carried out with isotonic saline, and clearances were obtained during the last 10 minutes of saline infusion and 10 minutes after cessation of the expansion. Finally, 30 minutes after the end of the ECVE, two more 15-minute clearances were obtained.
Group 5 (n‫)4؍‬
After two 15-minute control clearances, trandolapril (0.3 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ) and verapamil (0.5 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ) were infused into both renal arteries until the end of the experiment. Thirty minutes after the initiation of trandolapril and verapamil infusion, two additional 10-minute clearances were obtained, and a 5% ECVE with isotonic saline was performed during 45 minutes. Two clearances were obtained: during the last 10 minutes of saline infusion and 10 minutes after the end of this infusion. Finally, 30 minutes after the end of saline infusion, two more 15-minute clearances were obtained.
Analytical Methods
Renal clearances were taken during each experimental period to determine GFR, UNaV, UKV, and UV. Blood samples for hematocrit and plasma sodium, potassium, and inulin concentrations were also obtained during each renal clearance. GFR was measured by the clearance of inulin. Inulin concentrations were analyzed by the anthrone method. Concentrations of sodium and potassium were measured by flame photometry (Corning 435).
Statistical Analysis
The data for the two clearance periods for each condition were averaged for statistical comparisons because the fluid and solute excretions were in steady state conditions. There were no differences between the results obtained during both renal clearances of each period. Data are expressed as meanϮSE. Significance of differences in values of each period in the same group and kidney was evaluated using a one-way ANOVA and the Duncan multiple range test. Differences between the same period of different kidneys and groups were calculated with a two-way ANOVA and the Duncan test. 
Results
Group 1
Selected Abbreviations and Acronyms
Ang I, II ϭ angiotensin I, II CEI ϭ converting-enzyme inhibitor ECVE ϭ extracellular volume expansion GFR ϭ glomerular filtration rate L-NAME ϭ N G -nitro-L-arginine methyl ester MAP ϭ mean arterial pressure NO ϭ nitric oxide PG ϭ prostaglandin RBF ϭ renal blood flow UKV ϭ urinary potassium excretion UNaV ϭ urinary sodium excretion UV ϭ urine flow rate kidney, with a subpressor dose of L-NAME, induced a significant rise of MAP (PϽ.05) that was maintained throughout the experiment. The simultaneous inhibition of NO and PG synthesis in the right kidney provoked an increase of renal vascular resistance and a decrease of UNaV, UKV, and UV that was significantly greater (PϽ.05) than that induced by the PG synthesis inhibition in the left kidney. It can be observed (Table 1, Fig 2) that the simultaneous inhibition of NO and PG synthesis, before the ECVE, provoked a significant decrease (PϽ.05) of GFR (46%), RBF (43%), UNaV (90%), and UV (84%). The PG synthesis inhibition in the left kidney induced a significant decrease (PϽ.05) of RBF (12%), UNaV (60%), and UV (42%). The ECVE induced a significant increase (PϽ.05) of GFR in the right kidney to control levels, but RBF remained significantly decreased (PϽ.05) ( Table 1, Fig 2) . During the ECVE, GFR was similar in both kidneys, and blood flow was significantly lower (PϽ.05) in the right than in the left kidney. Similarly, it can be observed ( Table 1, Fig 3) that the renal excretory response to the ECVE was significantly lower (PϽ.05) in the right kidney (simultaneous inhibition of NO and PG synthesis) than in the left kidney (inhibition of PG synthesis). During the postexpansion period, UNaV and UV were also significantly greater (PϽ.05) in the left than in the right kidney. Table 2 and Figs 1, 2, and 3 show the effects of verapamil during the intrarenal administration of a cyclooxygenase inhibitor, when NO was reduced in the right kidney. Although not shown in Table 2 , the administration of L-NAME into the right renal artery and meclofenamate into both renal arteries induced an increase in MAP (from 119Ϯ6 to 137Ϯ6 mm Hg) and changes in the renal hemodynamic and excretory function that were similar to those found in group 1. The increase in renal vascular resistance was significantly greater in the right (NO and PG reduction) than in the left kidney (PG reduction). It can be observed (Table 2 and Figs 1 and 2) that MAP remained increased and blood flow decreased in both kidneys when verapamil was infused into the renal arteries. Verapamil partially abolished the renal vasoconstriction induced by the NO and PG synthesis inhibition, since GFR was similar to that found during the control period. However, verapamil infusion completely abolished the antinatriuretic effect induced by the meclofenamate administration, when intrarenal NO synthesis was reduced, since UNaV and UV were also similar during the verapamil infusion and control periods. It also can be observed in Table 2 that the administration of verapamil into the left kidney induced a significant increase of UNaV and UV and that RBF, UNaV, and UKV were greater in the left than in the right kidney before the ECVE.
Group 2
During the ECVE, GFR did not change and RBF increased significantly (PϽ.05) in both kidneys to levels similar to those found in the control period (Table 2 and Fig 2) . Nevertheless, RBF in the right kidney was lower than in the left kidney. These results indicate that the administration of this low dose of verapamil is not effective in blocking totally the renal vasoconstriction produced by the administration of a cyclooxygenase inhibitor, when NO synthesis is reduced. Finally, it can be observed in Table 2 and Fig 3 that the effect of the simultaneous reduction in NO and PG synthesis on the renal excretory response to ECVE was completely prevented by the administration of the low dose of verapamil. In fact, the ECVE-induced increases of UNaV and UV were significantly greater (PϽ.05) in this group than in the other groups of this study. Table 3 and Figs 1, 2, and 3 show the effects of trandolapril during the intrarenal administration of a cyclooxygenase inhibitor, when NO was reduced in the right kidney. Although not shown in Table 3 , the administration of L-NAME into the right renal artery and meclofenamate into both renal arteries induced an increase in MAP (from 127Ϯ4 to 139Ϯ4 mm Hg) and caused changes in the renal hemodynamic and excretory function that were similar to those found in group 1. Again, the changes induced by the simultaneous decrease in NO and PG synthesis were greater than those induced by the administration of the PG synthesis inhibitor. GFR and RBF decreased significantly (PϽ.05), to 24Ϯ4 and 144Ϯ9 mL/min, respectively, in the right kidney, and to 33Ϯ2 (NS) and 167Ϯ11 mL/min (PϽ.05), respectively, in the left kidney. Table 3 and Fig 1 show that MAP remained elevated when trandolapril (0.3 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ) was administered into both renal arteries. However, the administration of this CEI reduced significantly (PϽ.05) the renal vasoconstrictor effect induced by the administration of L-NAME and meclofenamate, since GFR was similar to that found during the control period and RBF was only slightly reduced (PϽ.05). With respect to the renal excretory function, it was only partially improved by the trandolapril administration. UNaV, UKV, and UV remained significantly decreased (PϽ.05) in the left kidney during the administration of this CEI (Table 3) . On the other hand, the reduction in Ang II synthesis completely abolished the changes in renal hemodynamic and excretory function induced by the PG synthesis inhibition in the left kidney. The ECVE provoked a significant increase (PϽ.05) of blood flow in the right kidney (Table 3 and Fig 2) . Table 3 shows that both GFR and RBF were similar in both kidneys during the ECVE. However, the ECVE-induced increases in UNaV, UKV, and UV were greater in the left than in the right kidney. These results indicate that Ang II synthesis inhibition does not prevent the altered excretory response to an ECVE, when NO and PG synthesis are reduced. genase inhibitor, when NO synthesis was reduced in the right kidney. Although not shown in Table 4 , the administration of L-NAME into the right renal artery and meclofenamate into both renal arteries induced an increase in MAP (from 125Ϯ4 to 142Ϯ4 mm Hg) and caused changes in the renal hemodynamic and excretory function that were similar to those found in group 1. It can be seen in Table 4 and Figs 1 and 2 that the increase of MAP and renal vasoconstriction were completely abolished by the simultaneous administration of verapamil (0.5 g ⅐ kg Ϫ1 ⅐ min
Group 3
Group 4
Ϫ1
) and trandolapril (0.3 g ⅐ kg Ϫ1 ⅐ min
). Furthermore, the administration of verapamil and trandolapril, before the ECVE, provoked a significant increase of UNaV (PϽ.05) but no significant changes of UV in either kidney.
During the ECVE there were no changes in renal hemodynamics and the increases of UNaV and UV were similar in both kidneys (Table 4, Fig 3) . During the postexpansion period, UNaV and UV remained similarly significantly elevated (PϽ.05) in both kidneys. Table 5 shows that the simultaneous intrarenal administration of verapamil and trandolapril into both renal arteries did not induce changes in MAP or GFR. It can be observed that the increases in RBF (during the ECVE) and in UNaV (before and during the ECVE) were similar in both kidneys.
Group 5
Discussion
The results of this study demonstrate that the simultaneous administration of low doses of verapamil and trandolapril has beneficial effects in treating the hypertension, renal vasoconstriction, and antinatriuresis induced by the acute intrarenal reduction of PG synthesis, when NO synthesis is decreased. In previous studies performed by our group, it was observed that the renal effects induced by NO and PG synthesis reduction are only partially prevented by the intrarenal administration of
). 8 The present study extends these observations by showing that the acute simultaneous intrarenal infusion of lower doses of verapamil (0.5 g ⅐ kg Ϫ1 ⅐ min
Ϫ1
) are effective in preventing the hypertension, renal vasoconstriction, and antinatriuretic effects induced by the intrarenal administration of a cyclooxygenase inhibitor when NO synthesis is partially reduced. These effects of the combined therapy were observed with and without increases of extracellular volume.
The role of NO and PG in the regulation of the renal hemodynamic and excretory function has been examined previously [1] [2] [3] 8 by the intrarenal infusion of L-NAME or meclofenamate at doses similar to those used in the present study. These doses are effective in reducing NO and PG synthesis. [1] [2] [3] 8 We believe that the dose of L-NAME used does not completely inhibit the intrarenal NO synthesis because the administration of greater doses produces a significant renal vasoconstriction. 16, 17 Trandolapril and verapamil were intrarenally infused in the present study because the objective was to evaluate the effects of these drugs in reducing the renal changes induced by the acute administration of a cyclooxygenase inhibitor, when NO synthesis is decreased. The interpretation of the results obtained would be more difficult if these drugs were infused intravenously because of the changes in arterial pressure.
The existence of an important interaction between NO and PG in the regulation of renal function has been suggested by the results obtained previously by our group. 2, 3, 8 It was demonstrated that the administration of a cyclooxygenase inhibitor elicits a rise of arterial pressure and an alteration of the renal hemodynamic and excretory function when NO synthesis is partially reduced. These results are similar to those found in the present study. The renal vasoconstriction seems to be secondary to the endogenous Ang II levels, since this effect was significantly reduced by the intrarenal infusion of trandolapril (0.3 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ). Furthermore, in a previous study 3 it was found that a greater dose of captopril (0.8 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ) completely inhibits the hypertension and renal vasoconstriction induced by the NO and PG synthesis reductions. However, the antinatriuretic effect is probably independent of the Ang II levels because this effect is not reduced by the administration of these CEIs. The decrease of sodium excretion could be secondary to an elevation of sodium reabsorption in the proximal 2, 8 and distal 18, 19 tubules and/or to a decrease of renal interstitial hydrostatic pressure and medullary blood flow. 20 -23 The administration of verapamil (0.5 g ⅐ kg Ϫ1 ⅐ min
) only reduced partially the renal vasoconstriction induced by the cyclooxygenase inhibitor when NO synthesis was partially inhibited. These effects are similar to those found in a previous study, 8 where a greater dose of verapamil was used (2 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ), with the only difference being that the natriuretic effect of this dose was greater than that found in the present study. When one takes into account the results obtained with trandolapril and captopril, 3 it can be suggested that verapamil inhibits the vasoconstrictor effect of Ang II on the afferent arteriole and that it only reduced partially this effect on the efferent arteriole. Indeed, GFR increased to control levels and RBF remained decreased with verapamil when NO and PG synthesis were reduced. This interpretation of our data is supported by the results obtained by Carmines et al. 24 These authors observed that the vasoconstrictor effects of Ang II on the afferent but not on the efferent arteriole were blocked with the administration of a calcium antagonist.
The infusion of verapamil not only inhibited the antinatriuretic effect produced by the NO and PG synthesis reduction but also increased the excretory response to the ECVE. This natriuretic response to the ECVE could be secondary to the greater arterial pressure, since it is known that calcium antagonists increase the natriuretic response to elevations of arterial pressure. 25 The increases of sodium and water excretion can be considered paradoxical if one considers that RBF was reduced. Nevertheless, previous studies have demonstrated that the natriuresis induced by calcium antagonists is independent of their hemodynamic actions. 25 The natriuretic response to ECVE during the verapamil administration is similar to that found in a previous study where a greater dose of verapamil was administered 8 and support the hypothesis that this calcium antagonist inhibits the increased sodium reabsorption induced by the NO and PG synthesis reductions. The results obtained do not indicate the mechanism by which verapamil inhibits the increased sodium reabsorption, but this effect could occur in proximal and distal tubules. It has been suggested that verapamil prevents the effect of the NO and PG synthesis inhibitors on the proximal tubule by blocking the antinatriuretic actions of Ang II in this tubular segment. 8 On the other hand, it has been reported that NO and PG regulate sodium reabsorption in the collecting tubule 18, 19, 23 and that calcium antagonists reduce sodium reabsorption in the same tubular segment. 25, 26 The natriuresis induced by verapamil can be due also to an increase in medullary blood flow, since it is known that calcium antagonists provoke an increase in medullary blood flow in salt-sensitive hypertensive animals, 25, 27 in whom NO production seems to be reduced. 6 The most important finding of this study is that low doses of trandolapril (0.3 g ⅐ kg Ϫ1 ⅐ min
) and verapamil (0.5 g ⅐ kg Ϫ1 ⅐ min
) are more effective when administered simultaneously in the treatment of the hypertension, renal vasoconstriction, and antinatriuresis induced by the NO and PG synthesis reductions. The effects induced by the simultaneous administration of these doses of verapamil and trandolapril are greater than those observed during the administration of greater doses of captopril (0.8 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ) 3 or verapamil (2 g ⅐ kg Ϫ1 ⅐ min
). 8 Therefore, the results obtained in this study suggest that a combination of low doses of trandolapril and verapamil is likely to be beneficial in the treatment of the hypertension, salt sensitivity, and renal vasoconstriction that could be induced by the intake of a cyclooxygenase inhibitor in those patients in whom the NO production is partially reduced. It has been suggested that during aging sodiumsensitivity of arterial pressure increases 13 and that there is an endothelial dysfunction. 6 It is also known that the intake of anti-inflammatory drugs is higher during aging. 12 Previous studies have reported that low doses of a calcium antagonist and a CEI have additive and synergistic effects in the decrease in arterial pressure when administered to normotensive or hypertensive patients. 9 -11,28,29 The synergistic effects in the treatment of hypertension during aging have been demonstrated in one study, 11 in which it was observed that the combination of 5 mg felodipine and 5 mg enalapril is more effective in reducing arterial pressure than the administration of a higher dose (10 mg) of felodipine or enalapril alone. However, the effects of both drugs on renal function were not evaluated in the study performed by Morgan and Anderson. 11 In summary, the results of this study provide new evidence that a combination of low doses of a calcium antagonist and a CEI improves the efficacy in reducing the renal effects induced by the acute administration of a cyclooxygenase inhibitor when NO synthesis is partially reduced. When the results obtained in previous studies of our group are considered, 3, 8 the results of this study suggest that low-dose dual therapy with a calcium antagonist and a CEI may be better than high-dose monotherapy with one of these drugs in the treatment of the renal effects produced by a cyclooxygenase inhibitor when NO synthesis is reduced.
